^
    13h
    Nutrition Awareness Among Women With Non-Metastatic Breast Cancer (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, UNC Lineberger Comprehensive Cancer Center
    New trial
    14h
    PRELUDE: A Prospective, Multicenter Registry to Observe the Treatment Patterns, Clinical Outcomes, and Decision-Making in Patients With Early Breast Cancer Eligible for EndoPredict® Testing (clinicaltrials.gov)
    P=N/A, N=2000, Recruiting, National and Kapodistrian University of Athens
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    EndoPredict®
    14h
    Improving Care for Rural Patients With Solid Tumors (clinicaltrials.gov)
    P=N/A, N=320, Recruiting, University of Colorado, Denver | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    15h
    CAFÉ: CTNNA1 Familial Expansion Study (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    CTNNA1 (Catenin Alpha 1)
    16h
    Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial (clinicaltrials.gov)
    P3, N=1156, Suspended, Alliance for Clinical Trials in Oncology | Recruiting --> Suspended
    Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Oncotype DX Breast Recurrence Score®Test
    |
    tamoxifen • letrozole • anastrozole • exemestane
    21h
    A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys (clinicaltrials.gov)
    P=N/A, N=8, Terminated, AHS Cancer Control Alberta | N=128 --> 8 | Trial completion date: Oct 2026 --> Sep 2025 | Recruiting --> Terminated | Trial primary completion date: May 2026 --> Sep 2025; Slow study accrual. Study sponsor decided to terminate the study in consultation with the DSMB.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    24h
    Evaluation of targeted and immune combination therapies in a rat model of hormone receptor-positive breast cancer. (PubMed, Proc Natl Acad Sci U S A)
    Here, we evaluated targeting candidates from this signature KMT5B/C and IKBKE using inhibitors A-196 and IKBKEi respectively, alongside anti-estrogen (fulvestrant) and a TGFβ blocking antibody (NIS793), both individually and in combination with αPD-L1, within this rat model. Comprehensive tumor profiling through polychromatic flow cytometry and single-cell RNA sequencing revealed that A-196 induced a luminal-to-basal shift in tumor epithelial cells, enhancing antigen presentation, whereas epithelial-to-mesenchymal transition was linked to fulvestrant resistance. Our findings underscore the value of the rat mammary tumor model for preclinical studies in ER-positive breast cancer and advocate for the further validation and potential clinical development of KMT5B/C inhibitors to enhance the efficacy and broaden the applicability of ICI therapy in cancer patients.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    ER (Estrogen receptor) • TGFB1 (Transforming Growth Factor Beta 1) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)
    |
    ER positive • HR positive
    |
    fulvestrant • nisevokitug (NIS793)
    1d
    Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing (clinicaltrials.gov)
    P=N/A, N=180, Not yet recruiting, Unity Health Toronto
    New trial
    1d
    Management during pregnancy and lactation of patients who are at high risk of breast cancer. (PubMed, Maturitas)
    Because of this, early risk assessment and tailored imaging are crucial for timely diagnosis. This review defines high-risk factors for breast cancer, and the management of these individuals during pregnancy and lactation.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HR negative
    2d
    EXERT-BCHC: Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning (clinicaltrials.gov)
    P=N/A, N=15, Recruiting, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Trial completion date: May 2026 --> Oct 2026 | Trial primary completion date: Nov 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    2d
    Single-Cell RNA Sequencing and Bulk RNA Sequencing Revealed the Interplay Between Intratumoral Heterogeneity and the Tumor Microenvironment in Breast Cancer. (PubMed, Cancer Med)
    Our comprehensive analysis of cell-cell communication networks among epithelial cells, fibroblasts, macrophages, and lymphocytes across BC subtypes focuses on ligand-receptor interactions. This study revealed that certain molecules within these networks exhibit significant prognostic value and therapeutic promise.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CD70 (CD70 Molecule) • SPP1 (Secreted Phosphoprotein 1)
    |
    ER positive • EGFR positive
    2d
    Generational trends in reproductive factors among women in the US: implications for breast cancer incidence. (PubMed, Breast Cancer Res)
    Over the past century, women in the US are attaining menarche earlier, more likely to have their first birth after age 30 and having fewer births. Parsing the extent to which changes in reproductive factors are contributing to the rising incidence of estrogen receptor positive breast cancer, especially in premenopausal women, is necessary to devise long-lasting and sustainable preventive strategies.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive